GlycoMimetics (GLYC) Announces Positive Update on GMI-1271 Phase 1/2 in AML; All Response Patients Seen with CR Rates
Tweet Send to a Friend
GlycoMimetics, Inc. (Nasdaq: GLYC) announced that results of its Phase 1/2 clinical trial on its lead drug candidate GMI-1271 continued ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
